343956-49-0

Upstream product

• 914637-96-0 diethyl 4-oxo-1,2-cyclopentanedicarboxylate 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 6261-04-7 2,3,4-tris(ethoxycarbonyl)cyclopentanone 
• 1703-61-3 rac-4-oxocyclopentane-1,2-dicarboxylic acid 
• 4373-15-3 1,2,3,4-butanetetracarboxylic acid tetraethyl ester 
• 4534-68-3 1,2,3,4-butanetetracarboxylic acid 

Downstream Products

• 90474-14-9 4-Methylene-cyclopentane-1,2-dicarboxylic acid 
• 198022-62-7 (2E)-3-phenyl-2-propenyl (1R,2S)-4-methylene-2-{[(2E)-3-phenyl-2-propenyloxycarbonyl]amino}cyclopentanecarboxylate 
• 198022-60-5 (+)-(1S,2R)-4-methylene-2-[(2E)-3-phenyl-2-propenyloxycarbonyl]cyclopentanecarboxylic acid 
• 198022-61-6 (+)-(1R,2S)-4-methylene-2-[(2E)-3-phenyl-2-propenyloxycarbonyl]cyclopentanecarboxylic acid 
• 198022-65-0 (-)-(1R,2S)-2-amino-4-methylenecyclopentanecarboxylic acid 

Relevant academic research and scientific papers

Novel antifungal β-amino acids: Synthesis and activity against Candida albicans

A series of novel β-amino acids has been synthesized and tested for their in vitro antifungal activity against Candida albicans. A steep SAR was observed. β-Amino acid 21 (BAY 10-8888/PLD-118) revealed the most favourable activity-tolerability profile and was selected for clinical studies as a novel antifungal for the oral treatment of yeast infections.

Efficient asymmetric synthesis of β-amino acid BAY 10-8888/PLD-118, a novel antifungal for the treatment of yeast infections

The β-amino acid BAY 10-8888/PLD-118 is currently being investigated in phase II clinical studies as a novel antifungal for the treatment of yeast infections. An efficient asymmetric synthesis of this compound is described. The key step employed a highly enantioselective, quinine-mediated alcoholysis of a mesoanhydride intermediate.